2021 SITC Online Sponsored Symposium | November 12, 2021 Leveraging comprehensive genomic data for diagnostic capabilities and composite biomarker discovery in immunotherapy Erin Newburn, MS, PhD Director, Field Application Scientist Personalis, Inc. To enable the identification of composite biomarkers that combine tumor- and immune-related information [...]
2021 SITC: Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy Background Typical liquid biopsy panels offer a limited understanding of tumor biology, potentially under-representing the heterogeneity of resistance in late-stage cancers. Here, diminished scope can result in undetected, therapeutically-relevant biomarkers which respond [...]
2021 SITC: Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome Introduction Comprehensive profiling of both the tumor and tumor microenvironment (TME) can help further our understanding of tumor progression and response to treatment. Many immune features can be extracted from transcriptomic data, including characterization of the immune infiltrate and profiling of the [...]
2021 SITC: Extensively validated HLA LOH algorithm demonstrates an association between HLA LOH and genomic instability Background Human Leukocyte Antigen (HLA) genes are critical for the presentation of neoantigens to the immune system by cancer cells. Deletion of HLA alleles, known as HLA loss of heterozygosity (LOH), has been highlighted as a key immune [...]
2021 SITC: Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST Background Metastatic gastrointestinal stromal tumors (GIST) are lethal tumors of the GI tract characterized by gain of function mutations in KIT or PDGFRɑ. Transient first-line control is achieved through the inhibition of tyrosine kinase signaling using the KIT inhibitor imatinib, [...]
InfiltrateID™ Quantification of the Immunocellular Content in the Tumor Microenvironment The emergence and success of immuno-oncology drugs in the treatment of several cancer types has transformed clinical practice. However, many patients do not respond to these drugs, compelling researchers and clinicians to broaden their search for biomarkers that can better [...]
Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics January 2021 Volume 20, 100111 The Personalis authors created Systematic HLA Epitope Ranking Pan Algorithm (SHERPA™), a novel pan-allelic machine learning algorithm for predicting MHC-peptide binding and [...]
Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms Clinical Cancer Research August 2021 Volume 27, Issue 15 This work evaluates the predictive strength of a composite biomarker, neoantigen presentation score (NEOPS), in a cohort of patients with late-stage melanoma. NEOPS incorporates damaging events [...]
2021 NeXT Level Biomarkers Symposium: Welcome Message Richard Chen, MD, MS Chief Scientific Officer Personalis, Inc.
Pharma Research Solutions Comprehensive genomics for drug discovery and preclinical development Genomic Insights for Optimizing Drug DevelopmentWith our Pharma Research Services portfolio of broad-content next-generation sequencing (NGS) assays and analytics, we can comprehensively address the needs of biopharmaceutical companies who wish to integrate high quality and high-accuracy genomic and/or transcriptomic [...]
